Australia - English - Department of Health (Therapeutic Goods Administration)

lupin australia pty limited - escitalopram oxalate, quantity: 19.155 mg (equivalent: escitalopram, qty 15 mg) - tablet, film coated - excipient ingredients: purified talc; magnesium stearate; croscarmellose sodium; colloidal anhydrous silica; microcrystalline cellulose; titanium dioxide; hypromellose; macrogol 400 - - treatment of major depression. - treatment of social anxiety disorder (social phobia). - treatment of generalised anxiety disorder. - treatment of obsessive-compulsive disorder.

Australia - English - Department of Health (Therapeutic Goods Administration)

lupin australia pty limited - escitalopram oxalate, quantity: 12.77 mg (equivalent: escitalopram, qty 10 mg) - tablet, film coated - excipient ingredients: colloidal anhydrous silica; croscarmellose sodium; magnesium stearate; purified talc; microcrystalline cellulose; titanium dioxide; hypromellose; macrogol 400 - - treatment of major depression. - treatment of social anxiety disorder (social phobia). - treatment of generalised anxiety disorder. - treatment of obsessive-compulsive disorder.

Australia - English - Department of Health (Therapeutic Goods Administration)

lupin australia pty limited - escitalopram oxalate, quantity: 12.77 mg (equivalent: escitalopram, qty 10 mg) - tablet, film coated - excipient ingredients: purified talc; croscarmellose sodium; magnesium stearate; microcrystalline cellulose; colloidal anhydrous silica; titanium dioxide; hypromellose; macrogol 400 - - treatment of major depression. - treatment of social anxiety disorder (social phobia). - treatment of generalised anxiety disorder. - treatment of obsessive-compulsive disorder.

Australia - English - Department of Health (Therapeutic Goods Administration)

lupin australia pty limited - escitalopram oxalate, quantity: 6.385 mg (equivalent: escitalopram, qty 5 mg) - tablet, film coated - excipient ingredients: magnesium stearate; colloidal anhydrous silica; purified talc; croscarmellose sodium; microcrystalline cellulose; titanium dioxide; hypromellose; macrogol 400 - - treatment of major depression. - treatment of social anxiety disorder (social phobia). - treatment of generalised anxiety disorder. - treatment of obsessive-compulsive disorder.

Australia - English - Department of Health (Therapeutic Goods Administration)

lupin australia pty limited - escitalopram oxalate, quantity: 6.385 mg (equivalent: escitalopram, qty 5 mg) - tablet, film coated - excipient ingredients: croscarmellose sodium; colloidal anhydrous silica; purified talc; magnesium stearate; microcrystalline cellulose; titanium dioxide; hypromellose; macrogol 400 - - treatment of major depression. - treatment of social anxiety disorder (social phobia). - treatment of generalised anxiety disorder. - treatment of obsessive-compulsive disorder.

Australia - English - Department of Health (Therapeutic Goods Administration)

pharmacor pty ltd - quetiapine fumarate, quantity: 172.704 mg (equivalent: quetiapine, qty 150 mg) - tablet, film coated - excipient ingredients: hypromellose; magnesium stearate; iron oxide yellow; povidone; macrogol 400; lactose monohydrate; sodium starch glycollate type a; titanium dioxide; calcium hydrogen phosphate dihydrate; microcrystalline cellulose - quetiapine is indicated for:,bipolar disorder,adults,? maintenance treatment of bipolar i disorder, as monotherapy or in combination with lithium or sodium valproate, for the prevention of relapse/recurrence of manic, depressive or mixed episodes,? treatment of depressive episodes associated with bipolar disorder (see dosage and administration),? treatment of acute mania associated with bipolar i disorder as monotherapy or in combination with lithium or sodium valproate,children/adolescents aged 10 to 17 years,? monotherapy treatment of acute mania associated with bipolar i disorder,schizophrenia (adults and adolescents aged 13 to 17 years),? treatment of schizophrenia

Australia - English - Department of Health (Therapeutic Goods Administration)

pharmacor pty ltd - quetiapine fumarate, quantity: 172.704 mg (equivalent: quetiapine, qty 150 mg) - tablet, film coated - excipient ingredients: povidone; titanium dioxide; microcrystalline cellulose; lactose monohydrate; magnesium stearate; sodium starch glycollate type a; macrogol 400; iron oxide yellow; calcium hydrogen phosphate dihydrate; hypromellose - quetiapine is indicated for:,bipolar disorder,adults,? maintenance treatment of bipolar i disorder, as monotherapy or in combination with lithium or sodium valproate, for the prevention of relapse/recurrence of manic, depressive or mixed episodes,? treatment of depressive episodes associated with bipolar disorder (see dosage and administration),? treatment of acute mania associated with bipolar i disorder as monotherapy or in combination with lithium or sodium valproate,children/adolescents aged 10 to 17 years,? monotherapy treatment of acute mania associated with bipolar i disorder,schizophrenia (adults and adolescents aged 13 to 17 years),? treatment of schizophrenia

Australia - English - Department of Health (Therapeutic Goods Administration)

pharmacor pty ltd - quetiapine fumarate, quantity: 115.136 mg (equivalent: quetiapine, qty 100 mg) - tablet, film coated - excipient ingredients: iron oxide yellow; magnesium stearate; microcrystalline cellulose; sodium starch glycollate type a; hypromellose; titanium dioxide; calcium hydrogen phosphate dihydrate; lactose monohydrate; macrogol 4000; povidone - quetiapine is indicated for:,bipolar disorder,adults,? maintenance treatment of bipolar i disorder, as monotherapy or in combination with lithium or sodium valproate, for the prevention of relapse/recurrence of manic, depressive or mixed episodes,? treatment of depressive episodes associated with bipolar disorder (see dosage and administration),? treatment of acute mania associated with bipolar i disorder as monotherapy or in combination with lithium or sodium valproate,children/adolescents aged 10 to 17 years,? monotherapy treatment of acute mania associated with bipolar i disorder,schizophrenia (adults and adolescents aged 13 to 17 years),? treatment of schizophrenia

Australia - English - Department of Health (Therapeutic Goods Administration)

pharmacor pty ltd - quetiapine fumarate, quantity: 230.272 mg (equivalent: quetiapine, qty 200 mg) - tablet, film coated - excipient ingredients: microcrystalline cellulose; povidone; sodium starch glycollate type a; hypromellose; magnesium stearate; calcium hydrogen phosphate dihydrate; macrogol 400; lactose monohydrate; titanium dioxide - quetiapine is indicated for:,bipolar disorder,adults,? maintenance treatment of bipolar i disorder, as monotherapy or in combination with lithium or sodium valproate, for the prevention of relapse/recurrence of manic, depressive or mixed episodes,? treatment of depressive episodes associated with bipolar disorder (see dosage and administration),? treatment of acute mania associated with bipolar i disorder as monotherapy or in combination with lithium or sodium valproate,children/adolescents aged 10 to 17 years,? monotherapy treatment of acute mania associated with bipolar i disorder,schizophrenia (adults and adolescents aged 13 to 17 years),? treatment of schizophrenia

Australia - English - Department of Health (Therapeutic Goods Administration)

pharmacor pty ltd - quetiapine fumarate, quantity: 115.136 mg (equivalent: quetiapine, qty 100 mg) - tablet, film coated - excipient ingredients: macrogol 4000; calcium hydrogen phosphate dihydrate; magnesium stearate; titanium dioxide; microcrystalline cellulose; lactose monohydrate; hypromellose; povidone; sodium starch glycollate type a; iron oxide yellow - quetiapine is indicated for:,bipolar disorder,adults,? maintenance treatment of bipolar i disorder, as monotherapy or in combination with lithium or sodium valproate, for the prevention of relapse/recurrence of manic, depressive or mixed episodes,? treatment of depressive episodes associated with bipolar disorder (see dosage and administration),? treatment of acute mania associated with bipolar i disorder as monotherapy or in combination with lithium or sodium valproate,children/adolescents aged 10 to 17 years,? monotherapy treatment of acute mania associated with bipolar i disorder,schizophrenia (adults and adolescents aged 13 to 17 years),? treatment of schizophrenia